|1.||Márquez, Javier: 11 articles (09/2015 - 05/2003)|
|2.||Dang, Chi V: 10 articles (11/2015 - 04/2009)|
|3.||Alonso, Francisco J: 10 articles (03/2014 - 05/2003)|
|4.||Lobo, Carolina: 9 articles (09/2015 - 11/2004)|
|5.||Romero-Gómez, Manuel: 9 articles (02/2015 - 07/2004)|
|6.||Cerione, Richard A: 9 articles (01/2015 - 09/2010)|
|7.||Matés, José M: 9 articles (03/2014 - 11/2004)|
|8.||Tsukamoto, Takashi: 8 articles (04/2014 - 07/2007)|
|9.||Szeliga, Monika: 7 articles (09/2015 - 02/2005)|
|10.||Curthoys, Norman P: 7 articles (07/2014 - 01/2002)|
12/01/1999 - "In several investigations, bacterial glutaminase was found to be a potent therapeutic agent against varieties of tumor, but it showed suppressive effects on haematopoietic systems and inhibitory effects on normal lymphocytic blastogenesis. "
04/15/2014 - "Taken together, ppp-GLS combines cell death induction, immune activation and glutaminase inhibition in a single molecule and has high therapeutic efficacy against cancer cells. "
01/01/2015 - "Bacterial L-asparaginases have been used as anti-cancer drugs for over 4 decades though presenting, along with their therapeutic efficacy, several side effects due to their bacterial origin and, seemingly, to their secondary glutaminase activity. "
10/21/1992 - "Bacterial glutaminase was shown to be effective in lowering the tumor burden with increased life span of the host. "
09/01/2015 - "Glutaminase is expressed in most mammalian tissues and cancer cells, but recent studies are now revealing a considerably degree of complexity in its pattern of expression and functional regulation. "
06/01/2000 - "Ehrlich ascites tumour cells transfected with the pcDNA3 vector containing an antisense segment (0.28 kb) of rat kidney glutaminase showed impairment in the growth rate and plating efficiency, as well as a shortage in the glutaminase protein and activity. "
01/01/2000 - "This result was confirmed by using the specific activity stain for glutaminase, which indicates that same enzyme activity is probably due to leakage of the same enzyme from malignant tissue into the ascites fluid. "
01/01/2000 - "Phosphate dependent glutaminase enzyme purified from mitochondria of malignant and non malignant ovarian tissue also showed bands of same molecular weight on 10% SDS-PAGE and gave same immunoreactive bands in trans-immunoblot like the purified glutaminase from ascites fluid. "
11/01/1988 - "Phosphate-dependent glutaminase was purified to homogeneity from isolated mitochondria of Ehrlich ascites-tumour cells. "
11/01/1988 - "Purification of phosphate-dependent glutaminase from isolated mitochondria of Ehrlich ascites-tumour cells."
|3.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
02/01/2009 - "Thus, in this study, we examined whether the glutaminase inhibitor and the gap junction blocker relieved experimental autoimmune encephalomyelitis (EAE) that is an animal model of MS. Here we show that the gap junction blocker carbenoxolone (CBX) and the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine (DON) decreased glutamate release from activated microglia and rescued neuronal death in a dose-dependent manner in vitro. "
03/08/1971 - "Glutaminase induced prolonged regression of established Ehrlich carcinoma."
12/01/1968 - "[Action of swine kidney L-glutaminase on Ehrlich carcinoma]."
01/01/2012 - "Also NK tumours, subtypes of myeloid leukaemias and T-cell lymphomas respond to ASNase, and ovarian carcinomas and other solid tumours have been proposed as additional targets for ASNase, with a potential role for its glutaminase activity. "
03/01/2003 - "Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas."
01/01/2000 - "Moreover, ascites fluid taken from patients of different age group with different stages of ovarian carcinoma revealed the presence of same glutaminase on 10% SDS-PAGE, and exhibited immunoreaction on ELISA, trans-immunoblot and dot immunoblot analysis."
|5.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
12/01/2011 - "The designed enzyme model with reduced Glutaminase side activity may help to develop a variant of enzyme drug through protein engineering by site-directed mutagenesis and thus to produce a drug with reduced side effect for treating acute lymphoblastic leukemia in children."
12/01/2011 - "In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia."
01/01/2015 - "In conclusion, L-asparaginase showed no glutaminase activity and good stability over a wide range of physiological conditions, and thus it could be used as a potential candidate for treatment of acute lymphoblastic leukemia. "
12/01/2011 - "L-Asparaginase, an enzyme drug used for the treatment of acute lymphoblastic leukemia and its effective usage in clinical arena is complicated owing to the significant Glutaminase side activity. "
10/01/2000 - "The use of Escherichia coli asparaginase II as a drug for the treatment of acute lymphoblastic leukemia is complicated by the significant glutaminase side activity of the enzyme. "
|2.||Glutamic Acid (Glutamate)
|4.||Small Interfering RNA (siRNA)
|7.||copper adenosine triphosphate
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Protein-Restricted Diet (Diet, Protein Restricted)
|5.||Transplantation (Transplant Recipients)